ZTS
NYSE · Pharmaceuticals
Zoetis Inc
$75.89
-2.82 (-3.58%)
Financial Highlights (FY 2026)
Revenue
8.94B
Net Income
2.52B
Gross Margin
71.9%
Profit Margin
28.2%
Rev Growth
+5.4%
D/E Ratio
2.72
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 71.9% | 71.9% | 28.1% | 28.1% |
| Operating Margin | 35.5% | 31.9% | 32.3% | 33.9% |
| Profit Margin | 28.2% | 26.8% | 25.1% | 28.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 8.94B | 8.48B | 12.02B | 10.95B |
| Gross Profit | 6.43B | 6.10B | 3.38B | 3.08B |
| Operating Income | 3.17B | 2.71B | 3.88B | 3.71B |
| Net Income | 2.52B | 2.16B | 3.02B | 3.10B |
| Gross Margin | 71.9% | 71.9% | 28.1% | 28.1% |
| Operating Margin | 35.5% | 31.9% | 32.3% | 33.9% |
| Profit Margin | 28.2% | 26.8% | 25.1% | 28.3% |
| Rev Growth | +5.4% | +5.4% | +1.9% | +24.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 12.06B | 12.06B | 18.38B | 22.65B |
| Total Equity | 4.44B | 4.44B | 33.02B | 33.90B |
| D/E Ratio | 2.72 | 2.72 | 0.56 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 3.29B | 2.97B | 4.97B | 3.99B |
| Free Cash Flow | — | — | 2.28B | 2.09B |